X
Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy
https://pharmaphorum.com/news/merck-takes-on-lilly-nektar-in-il-2-with-1-85bn-pandion-buy/
autoimmune disease
Genentech’s Rituxan approved for rare skin disease
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.